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Key message: Self-assessment of disease activity is feasible in rheumatoid arthritis, but its 
frequency decreases over time. 
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Sir, 
In rheumatoid arthritis (RA), regular assessment of disease activity is an integral part of a 
treat-to-target approach.[1] However, repeated, close-in-time consultations with the 
rheumatologist are not always feasible. In the Comorbidities and Education in Rheumatoid 
Arthritis (COMEDRA) trial, RA patients were trained to perform a self-assessment of Disease 
Activity Score on 28 joints (DAS28), termed auto-DAS (they were randomised to have this 
visit either at baseline, or after 6 months).[2] At the 6-month timepoint, the COMEDRA trial 
showed the feasibility of auto-DAS, and we found more therapeutic changes had been made 
in the auto-DAS arm.[2] The present letter reports the results of the open-label follow-up of 
this trial, after 3 years. The objective was to assess the feasibility over the long-term of auto-
DAS assessment, and determine the characteristics of patients adherent to auto-DAS. 
This was an open long-term (2-4 years) extension of the 6 month randomized controlled 
COMEDRA trial of patients with definite, stable RA. Ethical approval (ethical committee CPP Ile 
de France VI, number 8-14) and informed patient consent were obtained.  During a nurse visit, 
the importance of regular disease activity assessment was explained, as well as the principle 
of the DAS28. Patients were trained by a nurse to perform auto-DAS, using a video and 
teaching of self-assessment of joints (the training took approximately 30 minutes). It was 
suggested to them to perform this self-assessment regularly and to note it in a booklet. In the 
present follow-up, 2-4 years after the end of the trial, patients were seen in a face-to-face 
interview with a nurse and the frequency of auto-DAS was assessed through the auto-DAS 
booklet (N=247) and if unavailable, from patient questioning. Adherence to auto-DAS was 
defined as the performance of at least one auto-DAS more than 6 months after the end of the 
trial. Characteristics of adherent versus non adherent patients were compared by univariate 
and multivariate logistic regression analyses and included demographic and disease activity 
variables as well as the centre, according to its recruitment in the trial (centres were 
binarised as higher or lower than median inclusion number). 
Of the 970 recruited patients, 771 (79.5%) were followed up 3 years and had available data 
regarding auto-DAS: mean (±standard deviation) age 61 (±11) years, median [interquartile 
range, IQR] disease duration 15 [9 - 23] years; 615 (80%) were women and 534 (69%) were 
currently taking a biologic. There were no notable differences between those followed-
up or not (data not shown). The mean baseline and 3-year DAS28 scores (calculated by 
the health professionals) were respectively 3.1±1.3 and 2.8±1.4, the mean mHAQ was 0.38 
(±0.45). The inter-rater reliability (measured by intraclass correlation coefficient) of DAS28 
between health professional and patient was 0.50 [95% confidence interval 0.43-0.56] at 
baseline and it was 0.62 [0.57-0.67] at 3 years. After 3 years, 354 (46%) patients were 
adherent to auto-DAS. For adherent patients the median [IQR] number of auto-DAS 
performed was 5.4 [1.7 – 12.8] overall, i.e. 2.3 [0.8 – 5.9] per year. However among the 
adherent population, the number of patients who performed an auto-DAS at least once per 
year decreased over time (Figure) (p<0.0001). In the multivariate analysis, only larger 
inclusion centres were significantly associated to an adherent behaviour (odds ratio 2.9 [95% 
confidence interval 2.0 – 4.1], p<0.0001). 
These results confirmed the feasibility of auto-DAS. Auto-DAS may reflect flares and allow 
the health professional to obtain an overview of health status between visits.[3-5] These 
results further indicate that after a short training, many of these long-standing, moderately 
active RA patients continued to perform an auto-DAS, though the performance of auto-DAS 
decreased over time. It is of course possible that patients who self-reported autoDAS were not 
accurate. It is noteworthy that in this cohort, most patients did not receive any ongoing 
positive feedback on their auto-DAS. In the larger inclusions centres, auto-DAS adherence 
was higher. We hypothesise that a high number of patient inclusion reflected local strong 
involvement of physicians and nurses in the project. The results are suggesting a less 
optimal performance of the auto-DAS in the absence of discussion of the results of the auto-
DAS with the treating rheumatologist. It is noteworthy that patients in the present study had 
stable RA, usually in moderate disease activity. It is possible that auto-DAS is felt as 
worthwhile, when patients are flaring or otherwise doing poorly. Reversely, repeated 
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assessments may pall for patients in long-term stable disease.[6] The decrease over time of 
auto-DAS, and previous studies of between-visit assessments (such as e-health tools can 
provide) indicate a benefit from feedback from the health care providers, to keep patient 
motivation up.[6,7]. These data emphasize the importance of a clear communication between 
the rheumatology team and the treating rheumatologist in order to explain clearly the 
objectives and the potential benefit of this initiative. These results thus suggest the necessity 
of a regular reinforcement of this initiative; which might be optimally performed by the 
rheumatology team during the recommended annual systematic and comprehensive review 
supervised by the rheumatology team. [8] 
We conclude that self-assessment of disease activity is feasible in RA but positive 
reinforcement appears necessary. Further studies should analyse if outcomes are better for 
patients who perform self-assessments regularly. 
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Figure title. Percentage of patients performing at least one auto-DAS per year, over 
time 
 
 
Legend 
X axis year of follow-up after the trial 
Y axis percentage of patients performing at least one auto-DAS each year, among 
patients considered adherent (i.e., having performed at least one auto-DAS more 
than 6 months after the end of the trial). 
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